Indivior PLC and Opiant Pharmaceuticals, Inc. entered a definitive agreement, under which Indivior will acquire Opiant for approximately $145 million in cash, plus potential milestones for achievements during the relevant seven-year period by OPNT003 after its approval and launch. The transaction has been approved by the boards of directors of each company.   Opiant is a biopharmaceutical company developing treatments for addiction and drug overdose leveraging intranasal and injectable deliver...